IP Verse

Controlled Release Formulations Of Levodopa And Uses Thereof - EP2234963

The patent EP2234963 was granted to Impax Laboratories on Apr 8, 2020. The application was originally filed on Dec 26, 2008 under application number EP08866933A. The patent is currently recorded with a legal status of "Revoked".

EP2234963

IMPAX LABORATORIES
Application Number
EP08866933A
Filing Date
Dec 26, 2008
Status
Revoked
Jan 24, 2025
Grant Date
Apr 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LUIGIJan 7, 2021TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSJan 7, 2021D YOUNGADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007148238
INTERNATIONAL-SEARCH-REPORTUS2005203185
INTERNATIONAL-SEARCH-REPORTUS2006013875
INTERNATIONAL-SEARCH-REPORTUS2007148238
OPPOSITIONEP1262198
OPPOSITIONEP1964566
OPPOSITIONUS2006013875
OPPOSITIONUS2007003621
OPPOSITIONUS2007148238
OPPOSITIONUS2007275060
OPPOSITIONWO2009085306
SEARCHEP1262198

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Lewitt P A, Et Al, "Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): Clinical and pharmacokinetic studies", Neurology, (19890101), vol. 39, no. supp2, pages 45 - 53, XP055806526
OPPOSITION- Mylan Pharmaceuticals Inc, "Carbidopa and levodopa, Carbidopa and levodopa tablet, extended-release", (20200201), pages 1 - 18, XP055806522
OPPOSITION- NAGAYAMA et al., "The Effect of Ascorbic Acid on the Pharmacokinetics of Levodopa in Elderly Patients with Parkinson Disease", Clin. Neuropharmacol., (20041100), vol. 72, no. 6, XP008146474
OPPOSITION- Nagayama Hiroshi; Hamamoto Makoto; Ueda Masayuki; Nito Chikako; Yamaguchi Hiroshi; Katayama Yasuo, "The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease", CLINICAL NEUROPHARMACOLOGY, US, (20041201), vol. 27, no. 6, ISSN 0362-5664, pages 270 - 273, XP008146474
OPPOSITION- HAYASHI et al., "Physiological mechanism for enhancement of paracellular drug transport", Journal of Controlled Release, (19990000), vol. 62, doi:10.1016/S0168-3659(99)00031-0, pages 141 - 148, XP004363011
OPPOSITION- Hauser Robert A, European Neurology, "Levodopa: Past, Present, and Future", (20090101), vol. 6, no. 2, doi:10.1159/000215875, pages 1 - 8, XP055806525
SEARCH- NAGAYAMA HIROSHI ET AL, "The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease", CLINICAL NEUROPHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, (20041201), vol. 27, no. 6, ISSN 0362-5664, pages 270 - 273, XP008146474 [X] 1-6,11-15 * abstract * * page 271, column l, paragraph 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents